AbbVie's VIEKIRAX Approved in Japan for the Treatment of Genotype 1 Chronic Hepatitis C

By: via Benzinga
AbbVie (NYSE: ABBV) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved VIEKIRAX® ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.